Mdtech analyst that has allowed the WBB Securities cofounder to develop a reasoned perspective on how West Africa's Ebola epidemic might be humanely halted. Brozak also mentions small-cap names that could considerably enhance investors' portfolios.

CMRX announced its investigational broad-spectrum antiviral brincidofovir has been selected as one of two investigational agents to be evaluated in a clinical study with ebola. (ISIS) and (AZN) announced a strategic alliance to develop novel delivery methods for antisense oligonucleotides.

Tekmira Pharmaceuticals (TKMR) and European drug developer Bavarian Nordic (BAVA.CO) are receiving significant attention in early trading on Wednesday morning with announcements that their two distinct approaches to Ebola, a therapeutic and vaccine respectively, are advancing.

Chimerix, Inc. engages in the discovery, development and commercialization of oral antiviral therapeutics for various medical needs.